Sensory Ataxic Guillain-Barré Syndrome with Dysgeusia after mRNA COVID-19 Vaccination |
| |
| Authors: | Shunsuke Ogata Yoshito Ishii Keiichiro Asano Erena Kobayashi Shun Kubota Keita Takahashi Yosuke Miyaji Yuichi Higashiyama Hideto Joki Hiroshi Doi Michiaki Koga Hideyuki Takeuchi Fumiaki Tanaka |
| |
| Affiliation: | 1.Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan; 2.Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Japan |
| |
| Abstract: | Guillain-Barré syndrome (GBS) has occasionally occurred in people who have received coronavirus disease 2019 (COVID-19) vaccines. Dysgeusia is rare symptom of GBS. We herein report a rare case of sensory ataxic GBS with dysgeusia just after the second dose of the Pfizer-BioNTech COVID-19 vaccine. Although autoantibodies against glycolipids were not detected, immunotherapy with intravenous immunoglobulin and methylprednisolone pulse therapy effectively ameliorated the symptoms. Our report suggests that the COVID-19 vaccine may induce various clinical subtypes of GBS, including a rare variant with sensory ataxia and dysgeusia. |
| |
| Keywords: | vaccination, COVID-19, Guillain-Barré syndrome, sensory ataxia, dysgeusia |
|
|
